Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8836155 | 0.85 | ADORA1 (0.71) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL7431499 | 0.85 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL7439146 | 0.85 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL6287806 | 0.80 | ADORA1 (0.73) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL7644015 | 0.79 | ADORA1 (0.71) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL3686177 | 0.77 | ADORA1 (0.68) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8005373 | 0.77 | ADORA1 (0.76) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL3691346 | 0.77 | ADORA1 (0.64) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL3068195 | 0.76 | ADORA2B (0.64) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL787601 | 0.76 | ADORA2B (0.64) | ADORA1ADORA2AADORA2BADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | ADORA1, ADORA2A, TBXA2R | ADORA1 1/4885ADORA2A 2/4885ADORA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.